Increased dosage of donepezil for the management of behavioural and psychological symptoms of dementia in dementia with Lewy bodies

Psychogeriatrics

Volumn 16, Issue 3, 2016, Pages 202-208

  Manabe, Yuta ^a,b,c   Ino, Teruo ^c   Yamanaka, Katsuo ^c   Kosaka, Kenji ^b  

^a Yokohama Shintoshi Neurosurgical Hospital   (Japan)

^b Medical Care Court Clinic ^*  (Japan)

^c FUJITA HEALTH UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Alzheimer's disease; Behavioral and psychological symptoms of dementia; Cholinesterase inhibitors; Hallucination; Lewy bodies; Neuropsychiatric Inventory

Indexed keywords

DONEPEZIL; CHOLINESTERASE INHIBITOR; INDAN DERIVATIVE; PIPERIDINE DERIVATIVE;

AGED; ANXIETY; ARTICLE; BEHAVIOR DISORDER; BEHAVIORAL AND PSYCHOLOGICAL SYMPTOMS OF DEMENTIA; CLINICAL ARTICLE; CLINICAL TRIAL; DIFFUSE LEWY BODY DISEASE; DISEASE CONTROL; DISEASE EXACERBATION; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; DRUG WITHDRAWAL; EUPHORIA; FEMALE; GASTROINTESTINAL SYMPTOM; HEART ARRHYTHMIA; HUMAN; IRRITABILITY; MALE; MENTAL DISEASE; MENTAL DISEASE ASSESSMENT; NEUROPSYCHIATRIC INVENTORY; PARKINSONISM; PRIORITY JOURNAL; RELAPSE; SCORING SYSTEM; VERY ELDERLY; BEHAVIOR; COGNITION; DEMENTIA; DOSE RESPONSE; DRUG ADMINISTRATION; DRUG EFFECTS; LEWY BODY DISEASE; MIDDLE AGED; PSYCHOLOGY; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

AGED; AGED, 80 AND OVER; BEHAVIOR; BEHAVIORAL SYMPTOMS; CHOLINESTERASE INHIBITORS; COGNITION; DEMENTIA; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; INDANS; LEWY BODY DISEASE; MALE; MIDDLE AGED; PIPERIDINES; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 84937057075     PISSN: 13463500     EISSN: 14798301     Source Type: Journal    
DOI: 10.1111/psyg.12140     Document Type: Article

References (14)

1. McKeith IG, Dickson DW, Lowe J etal. Diagnosis and management of dementia with Lewy bodies. Third report of the DLB consortium. Neurology 2005; 65: 1863-1872.
2. Sultzer DL, Mahler ME, Mandelkern MA etal. The relationship between psychiatric symptoms and regional cortical metabolism in Alzheimer's disease. J Neuropsychiatry Clin Neurosci 1995; 7: 476-484.
3. McKeith I, Del Ser T, Spano P etal. Efficacy of rivastigmine in dementia with Lewy bodies: a randomised, double-blind, placebo-controlled international study. Lancet 2000; 356: 2031-2036.
4. Ikeda M, Mori E, Kosaka K etal. Long-term safety and efficacy of donepezil in patients with dementia with Lewy bodies: results from a 52-week, open-label, multicenter extension study. Dement Geriatr Cogn Disord 2013; 36: 229-241.
5. Mori E, Ikeda M, Kosaka K. Donepezil for dementia with Lewy bodies: a randomized, placebo controlled trial. Ann Neurol 2012; 72: 41-52.
6. Mori S, Mori E, Iseki E, Kosaka K. Efficacy and safety of donepezil in patients with dementia with Lewy bodies: preliminary findings from an open label study. Psychiatry Clin Neurosci 2006; 60: 190-195.
7. Manabe Y, Kosaka K. Efficacy of high-dose donepezil in the treatment of neuropsychiatric symptoms in cases of dementia with Lewy bodies. Clinical Psychiatry 2009; 51: 1165-1172 (in Japanese).
8. Dubois B, Tolosa E, Katzenschlager R etal. Donepezil in Parkinson's disease dementia: a randomized, double blind efficacy and safety study. Mov Disord 2012; 27: 1230-1238.
9. Homma A, Imai Y, Tago H etal. Donepezil treatment of patients with severe Alzheimer's disease in a Japanese population: results from a 24-week, double-blind, placebo-controlled, randomized trial. Dement Geriatr Cogn Disord 2008; 25: 399-407.
10. Rojas-Fernandez CH. Successful use of donepezil for the treatment of dementia with Lewy bodies. Ann Pharmacother 2001; 35: 202-205.
11. Perry EK, Haroutunian V, Davis KL etal. Neocortical cholinergic activities differentiate Lewy body dementia from classical Alzheimer's disease. Neuroreport 1994; 5: 747-749.
12. Darreh-Shori T, Meurling L, Pettersson T etal. Changes in the activity and protein levels of CSF acetylcholinesterases in relation to cognitive function of patients with mild Alzheimer's disease following chronic donepezil treatment. J Neural Transm 2006; 113: 1791-1801.
13. Lippa CF, Duda JE, Grossman M etal. DLB and PDD boundary issues diagnosis, treatment, molecular pathology, and biomarkers. Neurology 2007; 68: 812-819.
14. Rosenbloom MH, Finley R, Scheinman MM etal. Donepezil associated bradyarrhythmia in a patient with dementia with Lewy bodies (DLB). Alzheimer Dis Assoc Disord 2010; 24: 209-221.